Comparing musculoskeletal and connective tissue disorder risks of Teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)

Background Osteoporosis (OP) is a common skeletal disorder characterized by decreased bone mass and increased fracture risk. Anabolic agents such as teriparatide (TP) and abaloparatide (ABL) have been introduced to stimulate bone formation and reduce fracture incidence. However, whether their use increases the risk of musculoskeletal and connective tissue disorders (MCTD) remains unclear.